Is Arrowhead’s plozasiran becoming the RNAi drug to watch in extreme triglyceride disorders?
Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.
Pharma & Biotech
Pharma & Biotech
Why Vivatides Therapeutics’ $54m Series A matters for extrahepatic RNA therapeutics
Vivatides Therapeutics raised $54 million to advance extrahepatic RNA therapeutics. Read why this platform bet could reshape RNA drug development.